A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
Latest Information Update: 25 Jul 2024
At a glance
- Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin
- Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 12 Apr 2023 The study protocol amended as the patients in all arms undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.
- 02 Feb 2021 Status changed from not yet recruiting to recruiting.
- 21 Dec 2020 New trial record